Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non–Small-Cell Lung Cancer

Kitazono, Satoru; Fujiwara, Yutaka; Tsuta, Koji; Utsumi, Hirofumi; Kanda, Shintaro; Horinouchi, Hidehito; Nokihara, Hiroshi; Yamamoto, Noboru; Sasada, Shinji; Watanabe, Shun; Asamura, Hisao; Tamura, Tomohide; Ohe, Yuichiro

doi:10.1016/j.cllc.2015.03.008

Cited by 121 publications

(112 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PD-L1 status shows a good concordance between small biopsies and resected specimens21; still, compared to WTSs only a small tumor area can be analyzed, this has to be considered as a limitation of the following analysis.…”

Section: Resultsmentioning

confidence: 99%

Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer

Aust

Félix

Auer

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Immune-evasion and immune checkpoints are promising new therapeutic targets for several cancer entities. In ovarian cancer, the clinical role of programmed cell death receptor ligand 1 (PD-L1) expression as mechanism to escape immune recognition has not been clarified yet. We analyzed PD-L1 expression of primary ovarian and peritoneal tumor tissues together with several other parameters (whole transcriptomes of isolated tumor cells, local and systemic immune cells, systemic cytokines and metabolites) and compared PD-L1 expression between primary tumor and tumor recurrences. All expressed major histocompatibility complex (MHC) I genes were negatively correlated to PD-L1 abundances on tumor tissues, indicating two mutually exclusive immune-evasion mechanisms in ovarian cancer: either down-regulation of T-cell mediated immunity by PD-L1 expression or silencing of self-antigen presentation by down-regulation of the MHC I complex. In our cohort and in most of published evidences in ovarian cancer, low PD-L1 expression is associated with unfavorable outcome. Differences in immune cell populations, cytokines, and metabolites strengthen this picture and suggest the existence of concurrent pathways for progression of this disease. Furthermore, recurrences showed significantly increased PD-L1 expression compared to the primary tumors, supporting trials of checkpoint inhibition in the recurrent setting.

show abstract

Section: Resultsmentioning

confidence: 99%

Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer

Aust

Félix

Auer

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…As a feature of our PD-L1 scoring method (H-score), as long as the specimens contained a sufficient amount of tumor cells, they were regarded as being eligible for evaluation. In non-small cell lung cancer, Kitazono et al showed that even small samples from a needle biopsy are adequate for evaluating PD-L1 expression in paired specimens (concordance, 92.4%) (35). Specimens obtained through noninvasive procedures and enabling a precise pathological diagnosis are needed even more in this era of biomarker-driven therapy.…”

Section: Discussionmentioning

confidence: 98%

Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy

Katsuya

Horinouchi²,

Asao³

et al. 2016

Lung Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…They have been applied to tumour specimens collected days, months or years before initiation of anti-PD1 treatment; specimens taken a long time before treatment might not reflect PDL1 status at the time of therapy. Specimens can be collected by various procedures including surgical resection or needle biopsy; focal PDL1 expression as described above for the adaptive immune resistance phenomenon could be missed in small tumour specimens, resulting in a false-negative PDL1 evaluation 64 . Furthermore, not all anti-PDL1 mAbs produce similar staining results 46 .…”

Section: Immunological Biomarkersmentioning

confidence: 99%

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

et al. 2016

View full text Add to dashboard Cite

With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma, non-small-cell lung cancer and kidney cancer, and additional immune checkpoints being targeted clinically, many questions still remain regarding the optimal use of drugs that block these checkpoint pathways. Defining biomarkers that predict therapeutic effects and adverse events is a crucial mandate, highlighted by recent approvals for two PDL1 diagnostic tests. Here, we discuss biomarkers for anti-PD1 therapy based on immunological, genetic and virological criteria. The unique biology of the CTLA4 immune checkpoint, compared with PD1, requires a different approach to biomarker development. Mechanism-based insights from such studies may guide the design of synergistic treatment combinations based on immune checkpoint blockade.

show abstract

Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non–Small-Cell Lung Cancer

Cited by 121 publications

References 26 publications

Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer

Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer

Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Contact Info

Product

Resources

About